Andere talen Milestone Pharmaceuticals Inc.

Aandelen

MIST

CA59935V1076

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,54 ^USD	-2,53%		-6,10%	-7,78%

08/04	Milestone Pharmaceuticals kondigt Etripamil-gegevens aan die aantonen dat pati? vermogen om terugkerende PSVT zelf te beheren, gepresenteerd op de jaarlijkse bijeenkomst van het American College of Cardiology	CI
28/03	Milestone Pharmaceuticals dient aanvraag voor een nieuw geneesmiddel voor etripamil opnieuw in bij de FDA	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium	17/04
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting	08/04
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting	08/04
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference	03/04
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences	01/04
Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA	28/03
Milestone Pharmaceuticals : Corporate Presentation	28/03
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia	28/03
Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia	28/03
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update	21/03
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Milestone Pharmaceuticals : Corporate Presentation	07/03
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference	29/02
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants	29/02
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants	28/02
Milestone Pharma Shares Rise 25% After Plans to Resubmit Etripamil NDA	26/02
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT	26/02
Milestone Pharmaceuticals Inc. Announces Plan to Resubmit NDA for Etripamil for the Treatment of Psvt	26/02
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST	23/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Milestone Pharmaceuticals Inc.

Aandelen

MIST

CA59935V1076

Andere talen

Filters